Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case (Q40688211)

22 September 2017

Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case (English)

1 reference

22 September 2017

S Deuffic-Burban

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27144512%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

D Obach

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27144512%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

V Canva

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27144512%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

S Pol

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27144512%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

F Roudot-Thoraval

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27144512%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

D Dhumeaux

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27144512%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

publication date

4 May 2016

1 reference

Journal of Viral Hepatitis

22 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27144512%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27144512%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

page(s)

767-779

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27144512%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27144512%20AND%20SRC:MED&resulttype=core&format=json

New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives

5 June 2020

cites work

1 reference

Sofosbuvir for previously untreated chronic hepatitis C infection

21 January 2018

1 reference

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

21 January 2018

1 reference

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

21 January 2018

1 reference

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

21 January 2018

1 reference

Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

21 January 2018

1 reference

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

21 January 2018

1 reference

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

21 January 2018

1 reference

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

21 January 2018

1 reference

Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).

21 January 2018

1 reference

Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients

21 January 2018

1 reference

Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease

21 January 2018

1 reference

Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus

21 January 2018

1 reference

EASL recommendations on treatment of hepatitis C 2014.

21 January 2018

1 reference

Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis

21 January 2018

1 reference

Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

21 January 2018

1 reference

Valuing EQ-5D using time trade-off in France.

21 January 2018

1 reference

Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon alpha-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany.

21 January 2018

1 reference

Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs.

21 January 2018

1 reference

Cost-effectiveness of novel regimens for the treatment of hepatitis C virus

21 January 2018

1 reference

Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults

21 January 2018

1 reference

EASL Recommendations on Treatment of Hepatitis C 2015

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/JVH.12546

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27144512%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

1 reference